SUPN - Earnings call transcript Q1 2020 | Supernus Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Supernus Pharmaceuticals First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time.

As a reminder, this conference call is being recorded.

to Investor conference Pharmaceuticals. Relations like Vozzo to now Westwicke of representative would turn over the Peter I for Supernus

may begin. You

Peter Vozzo

joining company conference call. Thank thank after results. the Pharmaceuticals morning, Good the Yesterday, press quarter us market, release of for these the first results you, Supernus a today financial everyone, XXXX close for issued Lisa. you and announcing

is me Jack Greg at call with the today made call Khattar; Patrick. Chief the Chief of Officer, are the On Executive ir.supernus.com. via Officer, and Financial Today’s section Investor being available Supernus’ Relations website company’s

Following remarks we the open questions. call to by management, will

results During the perspective of trends including uncertainties, not Form and of company’s the may risks XXXX future and Annual company’s Factors certain course those forward-looking those statements. future noted Actual forward-looking differ involve performance information. performance. Any on on forward-looking existing such section statements guarantees management statements the Risk current make projected statements in These the are may regarding Supernus’ and events this Report these of materially from future and forward-looking in call, reflect XX-K.

the recorded at discussed. this Since who For to May replay, listening of topics held company may call the on then, announcements approximately XXXX and to the is additional you may X, X:XX related the A.M. being Time. benefit those of be Eastern made have

Supernus the except Please releases any company’s as with laws. applicable current SEC. to disclaims by securities the update reference most press forward-looking required recent obligation filings these statements, and

call turn now Jack. the will I to over

Jack Khattar

results discuss to morning, our thanks join we as the and Good taking developments. and time everyone, Peter. you, recent Thank XXXX first quarter us for

the moment development meet criteria many, ideal I take we a quarter and strategic two over deal. couple for we priorities if of discuss want announced transactions I to our first all corporate not, the These last the results, of have corporate weeks. Before transactions to an highlight

in diversify could XR help assets that then time could earnings generic. were us growth our our late-stage and base, to recall, Trokendi launched that might transition get followed priorities you future by be once goes revenue bring As asset commercial the a and with could to

to SPN-XXX. we have our we the with had also replenish launched pipeline setback and SPN-XXX We after

And finally, transaction a reasonable with that this fair to be don’t weaken accomplish sheet. all terms wanted we with our a can that deplete or and balance done

that we are were all able quarter in accomplish CNS with very to this close partnership. the this the of that and WorldMeds pleased the is to We portfolio of acquisition targeted US Navitor

of portfolio late-stage This the for Supernus three transaction that a marketed portfolio, WorldMeds. including development. product a and to is candidate to in our First, starting portfolio CNS the current US established acquisition and brings robust with in products neurology synergistic

respectively. an future XXXX, to and in $XXX $XXX million, are that of sales earnings payment the commercial In and approximately upside $XX milestones of deal generated of consists business. million million regulatory million of aligned $XXX upfront structure these operating products with net the The and up and

in expected for of primarily is the approved is late-stage launch, if second-half targeted Pump, the NDA a This XXXX. by upside Infusion this second-half an driven the a product Apomorphine is candidate which and for of year the FDA, submission by

launch support neurologists. and approximately salesforce significant to augment XXX specialists addition earnings, currently acquired will This building the us with personnel target representatives, high-quality will revenues disorder the sales salesforce SPN-XXX and who we to bring selective the will movement to group at the Supernus In approximately portfolio a psychiatry. of primarily in be of of future XX coverage

strong and augmenting and patient in Also, specialty with support a resulting our current platform we important capabilities commercial be capabilities. and will orphan acquiring the well-rounded commercial full areas, drug capabilities in pharmacy

NV-XXXX SPN-XXX. depression. for often Pharmaceuticals development suffering involves which that opportunity from NV-XXXX, joint orally in mTORCX, is suppressed small a active and its is first-in-class option agreement Navitor second with mTORCX people The directly or the molecule activator activates

demonstrated depressions, in This with with a in by have safety of clinical of which a improvement early and oral favorable and Phase and of I depression. proof-of-concept patients single profile, tolerability. data in agent treatment-resistant highly characterized potentially rapid dose NV-XXXX tolerability symptoms rapid can action a core differentiated showed sustained onset favorable

of target of FDA the Regarding SPN-XXX, X, prepare end for regarding XXXX. November with has the remains its we of PDUFA XXXX. the to NDA, continue engaged action launch commercial date SPN-XXX company The which at a

March put in Phase program reached COVID-XX. to patients The targeted additional hold the approximately in due impact III SPN-XXX of of on was adult with before enrollment XX% enrollment

ensure We prior are schedule data initially to potential can treatment. efforts second-half of year. with outbreak the this This the of completion the virtual in progress was to ahead COVID-XX of subjects employing that enrolled currently trial

trial the use that the expand study, pushed Depending be if will approved the us beyond may from can help on by restart in when company important out an and potentially of complete is the end market. enrollment trial the the of this This data FDA SPN-XXX, year. adult the

conduct to have on development exciting of transactions, as US our our SPN-XXX These from with our the announced best augmented priorities return been pipeline, transactions. That resources from Regarding our mid add the the partnership to our on with business of very transaction. portfolio projects rest Apomorphine pipeline WorldMeds allowed reset recently reassessment late-stage some Navitor R&D to able we programs mentioned investment. and a the Infusion and to focus earlier, to Pump us

of the estimated the result, disorder. launch and bipolar SPN-XXX the other to timing the potential of the including a SPN-XXX of As of the and factors, treatment terminate investment, decided for required given development company

capabilities molecule transactions, biologics the expertise development drug addition will in its small and medical corporate diversified. that device in in new previously to pipeline mentioned have well Supernus and with Furthermore, a development is

neurological Apomorphine SPN-XXX and mid-stage pipeline other to XX include epilepsy, and disorders. indications Pump. late-stage will and additional for include MYOBLOC The potential Infusion a the treatment-resistant And will the pipeline SPN-XXX for early depression new

Trokendi as growth reported XR XXX,XXX Trokendi first X% showed a increase flat. XXXX, were first quarter of quarter about reached to portfolio, the last XR while IQVIA, essentially first which for compared to is by current XR for on the Oxtellar prescriptions, XX% Moving of Oxtellar total the year, quarter XXXX. prescriptions XR over commercial and

XR in both which the plans. Trokendi Oxtellar January and with XR, the February, our to expectation deductible see first line first was in started in the descriptions high you softness quarter the in quarter and with due For typically effect of for decline

for was in the due Oxtellar in COVID-XX partially where by February, However, to Trokendi offset and in reflecting this compared XR prescriptions to prescriptions softness XR update impact. grew for XX% the XX% March, prescriptions

of the government medical field and interactions pandemic teams to response professionals public stay-at-home meetings. agencies, virtual to salesforce have and officials our COVID-XX In and and health from affairs face-to-face shifted recommendations healthcare calls the with

of Trokendi XR the service this time, hand been to allowed and products XR customers to while This Oxtellar continue to available inventory families. be physicians, impacted, critical both patients The to protecting the and company health supply us their to during for and continue and has employees of on of needs patients. the our adequate not has

continuing Depending the on prescription lasts, the starting it second a quarter. COVID-XX impact April situation of see the and how with negative least through at and to we month long on expect

results second the impact XXXX WorldMeds by pandemic, we first products the As acquisition the quarter anticipated the from of in of partnership COVID-XX quarter night and release, CNS uncertainty press the announced last given the company caused to no its suspending and XXXX full-year than of issued the previously XXXX expects full-year XXXX guidance. Pharmaceuticals, of Navitor financial company update with the always. reinstate second later financial results is announcement as quarter The guidance US

on our more details turn over Greg, who to now fourth the call full-year provide and will will I financial performance. quarter

Gregory Patrick

Thank and good you, Jack, morning, everyone.

refer please yesterday’s first As press results, I review our release. to quarter

Total comprised and sales an XX% $XX sales royalty $XX quarter million, of $X compared million in same net to Total product of of of first increase of net revenue million XXXX million $XX and first was was the for of product XXXX. million, revenue in over revenue year. last royalty the quarter revenue million quarter $X of as $XX

the XXXX sales the of As XXXX, quarter first could first in $XX to we XXXX. the previously than first first the that remained of for disclosed, approximately phenomena be comparison quarter that This of distributors inventory cause net the XXXX. sales net favorably product decreased levels draw lower At in their wholesalers, of inventory products pharmacies quarter our compared this as time, down estimated quarter and year-over-year had levels of impacted million constant. product inventory

million product period. XXXX, For in for Oxtellar to million, XR year $XX were $XX compared net million, quarter compared to product Net $XX sales $XX year of prior first period. the Trokendi for prior the was in the XR sales million

for adult, by the the XXXX. Turning now million quarter of first was $XX increase in were was SPN-XXX initiated or $XX driven to higher expenses primarily development million prior million for expenses. in year period. program This than III XXXX, Phase the enrollment in $X late and which Research

$XX quarter SG&A a in in million expenses. the a prelaunch million, employee-related for decrease compared to offset were increase expenses due marketing partially SPN-XXX, primarily expenses of in The products associated to SG&A with for is by expenses first the year and decrease $XX commercial in activities period. XXXX prior

operating Operating XXXX offset to modestly million, $XX expenses sales, for the due compared in was The partially $XX product higher XXXX. net expenses. to first higher of by quarter were million increase primarily

first per Net for basis, or XX% $XX $X.XX XXXX. earnings diluted or quarter were as on share per to XXXX, million of compared a $X.XX an quarter for diluted $XX first of share share, increase the the million, diluted

had in securities, $XXX cash, company quarter long-term decrease unrealized million marketable long-term securities, XX, cash marketable of market to This equivalents, the losses of XXXX. in first primarily of XXXX. and December $XXX XX, As volatility XXXX, March as million attributable securities, to the from marketable on resulting compared was

will to call I back questions. operator now the for the turn

Operator

line of question And Instructions] comes first Cacciatore your the Cowen Ken and Company. of from [Operator

Ken Cacciatore

actually acquired had guys. newly assets. to a morning, of questions Good acquired just the be couple I or soon about

been very APOKYN, years. first the durable a product on it’s well and just So wondering over very doing

differently? if growth? US it been here how anything at and look talk that Is you analyze so, can about marketing. you why? maybe that do the there an opportunity As Is to you has And would inflect there WorldMeds

And kind pipeline understanding, bit to are Parkinson’s? the for within could want us Apomorphine the the little this can either my brain it’s wouldn’t both? just way? wondering as Why question Apomorphine or you. opportunity? then It’s a end-stage And program, simple. patient if options levodopa? your use is Thank And more the Pump, maybe the about stimulation opposed I’m why you describe deep Duopa. just frame try a my on patients? you Could continuous to that, of you for of talk along What

Jack Khattar

Ken. Yes. Hi,

very Regarding the of Apomorphine actually APOKYN in is as as molecule around a therapy for franchise, treating a drug the franchise mainstay a episodes. while. a the for It’s far been has good Parkinson’s been disease. as

as – the resources phenomenal back, done as to concerned WorldMeds and single-digit business and with a level it has way building in sales forth. it’s a are And used phenomenal it job bring job US be where constrained really so today, somewhat the is building far and franchise to that product the actually at

market with of who our of and resources potentially because whitespace experience a and are product. the point the this. with with the like this product, the either hopefully what put out for treatments, There knowledge, the expanding do And a with to the a really of therefore, forward the it lot portfolio really matured of could is that additional could we – to is episodes meaning the experience potentially lot call this behind molecule hasn’t we patients product not awareness, use would look there, we in

of areas of lot growth potential a see here. we So

the also opportunity representatives, bit about there potential as salesforce well. the little firepower a to is is As product, mentioned, XX add behind I that an more a and expand that is whether sales

have and fact aspect synergies grow bet can we portfolio Parkinson’s definitely the here, neurology forth. on migraine so and on and the can take build where you them, these epilepsy and that potential of portfolio we that the at also the we’re every So advantage businesses, between looking in

certainly, So many for be really will the ways grow we looking franchise. to

for Apomorphine these course, franchise because addition then options to to And limited. because current franchise, that the speak, expands and of in patients augments the out are very excited pump, fairly we’re the so that, even there about the

to invasive consider pump gastric products the where forward going with invasive levodopa, all the be of As and certainly There it’s a for invasive you put you rush be considered brain for mentioned, gel patient the be other then deep you is surgery is the to. we to something these the not stimulation that to to in room tube, a appropriate would position But a be to profile. able to treatment or look procedures. potentially used surgery before everybody

as occupy these can very that think treatment product, patients and option. we of is the really very clearly, lot give such So nice we Apomorphine Infusion there with space feasible to viable a a a there Pump

is as mentioned finally, far very earlier, I really I mean, as And it a as effective Apomorphine, molecule. then

announced the You we clinical data to efficacy pump, it. might the we recall, pen is close on some the transaction, nothing well when – as went really actually through the as really the Apomorphine, comes

lot studies different activity Although scale reduction which data of and a III patients the of forth, those are so very in the pump Parkinson scale, the Apomorphine well common mobility pen, mean, and and none. data second the exciting really a measuring from is on with so to is from forth, points gathered UPRDS improvement as, the molecule its the I the Phase with as and very

is a existing but really programs powerful what or the products, that for itself the fact treatment just that’s not about, Parkinson’s. molecule fairly also And excites the us

Ken Cacciatore

you. Thank

Operator

from comes David the of question next Jefferies. your line Steinberg of And

David Steinberg

morning. of a and the physician the COVID interact questions A on time therefore, during A company managements. launch more reps lot Thanks see less the patients with and crisis have sales pending and couple of to XXX. groups good to of lot virtually

Just And your then XXX? updates research to are activities? whether And related more so, any it’s the payer of opportunity extensive Thanks. what you to if on highlights? afforded an some engage prelaunch curious in on that,

Jack Khattar

Yes.

we’ve Regarding more the physicians, to data the the and to practice the a not able have a and in, activities we’re you’re through these time have very all do absolutely situation many don’t bit little active engage prelaunch right. been – that points because fact They also education. living them are days. they going Actually, unfortunately,

a for active a on physicians, for we is website, patients of major to educate to to the lot launch but well website of good very, molecule, not parents, the for really program, more educating educational the So disease, about in have as really physicians which preparing materials also consumers, data we outreach our our forth, the look we’ve ADHD, that what for a to education, treatment digital very so so and about about been caretakers, space, only a and the as themselves, program, forth, SPN-XXX. have and in

these pointed it able But a these out, important made to so So launch. of situation, way COVID you speak, the the plans before in for we reach that, out important that situation. we even to were as very given will in to them good place really constituencies advantage and have all more COVID be our take really to

have was for As as clearer the get to the ongoing or we launch. far the have the as with and payer research, – obviously, be idea we of will launch day coverage about that close ongoing our kind one, may much, much discussions continue contracts before And of, to a we payers. from we

action about its published all the premature we It’s a for that nothing give you made it’s reuptake also data scientific almost atomoxetine we’ve So own. its new truly on little bit that But regarding not that atomoxetine, me the especially a of uniqueness historically surprising its very a really versus to definitive. is another of the class data, the norepinephrine it’s inhibitor. statements the or positioning, of drugs light it in not mechanism of product,

than serotonin atomoxetine. component different in The plays was the that’s SPN-XXX, got clinical which important, very, data mechanism very this very and a we is profile. why of different its with very And it role

it its is, extremely they differentiation, of with now way it. all as why data payers, out did Phase So favor profile product of came is, and we not also what as this the far the in the why understand but the well the has played with the physicians and III only

Operator

Stifel. line next the question your of comes Nick Rubino of And from

Nick Rubino

about Rubino the of second-half is guys thinking as Annabel. them, This of like? for look them year, going plans the salesforces on to making are salesforce what or In What prepare the everyone. Is separately? the any be you overlap WorldMeds? to kind you then Nick you for wholly there are and integration Hey, SPN-XXX develop

kind of notice March, on jumped due We of just did the the the Oxtellar markets if erode a prescriptions? And in went up. month steadily year-over-year, apologies this. over of trend was you But gross-to-net mostly we caused those those late, in the quarter? minute this kind would and then so throughout And figured what you one Was a March in there tick same Trokendi? and kind for it XX-day Thank to of especially you. improvement

Jack Khattar

Yes.

the building the are Regarding plans salesforce and salesforce as far same behind the activities SPN-XXX. our plans, point as at this still psychiatry

been in and from products. and on will US continue Parkinson’s focus to come to salesforce WorldMeds have in those will So us the us plans place. will place The join to continue that

together potentially I we that, forth, that capabilities. to some ways all point, like create mentioned It’s settle. do But exactly see and salesforce to how are is when synergies will As at that obviously, this we do earlier, putting the really anything SPN-XXX how we’re within things so that and process launch our will augment transaction a that this. there of or not to do augments

of a marketed So now of feel have products. we portfolio with course, you marketed SPN-XXX, with products six five and,

to have these We do plenty all on of products.

every Specifically, course, with the the but we here XXX, perspective, it that perspective, because that angle make Parkinson’s marketing we are business to as can also salesforce from of be portfolio growth we far sure with as a every acquiring, potential grows. opportunity other will exploring specifically

are perspective. a synergies overlap and call there from potentially also physician So

might bit differently So allocate the the to be little brands. a we across able different resources

a as acquisition clearly, the continuing looking the which in well works, for is is here, this us preparing the we’re foundation really the speak, for transaction, in psychiatry. as where major as forward as psychiatry prepare we So to all for and closing

let that. to Regarding gross-to-net, respond Greg I’ll

Gregory Patrick

Right.

of in terms So Nick, at. what looking exactly clear you’re I’m not

general, basis gross-to-net quarter offline. sequential Trokendi taking to a just this better So the do particularly first for we maybe the in we be from year But, XR. of might increasing on year, of last discussion this off deductions, see fourth quarter

The has around has the investors basic observed that. that past over theme from is which year, the company not what communicated and changed to

X% XR, got intensification an by the increases, offset price increase For wholly not, being Trokendi gross-to-net effect deductions. of plus if price combined the increases of year-over-year, largely, volume is

has the bit than a higher XR, little it’s on those been of combination for a little Oxtellar have been plus price increases, XR, volume a clearly intensification For at The bit a than more gross-to-net impacts you makes what’s increases same harder or Trokendi one-time underlying do continuing somewhat of impacts in have the that basis year-over-year. which phenomena, percentage different. gross-to-net versus deductions. on But and discern the sequentially to little it going

products to headwinds both we enrich really continue refill continue then to programs, the by to The that fill patients that continue, and same. with the we face drive Co-pay company’s which payments is their are to driven prescriptions. to

seen consistently then as the which have managed gross-to-net from care of the we the me, And of gross-to-net deductions very intensification company fees, excuse care the either ask an managed works. or or companies fee-for-service from, the regards, for programs, admin two combination with for – the

you talk this to to glad about So offline.

be might little a more that bit think, I efficient. Thanks.

Nick Rubino

Sounds you. good. Thank

Operator

Your Sandler. next David line question Piper with from comes of the Amsellem

David Amsellem

Thanks.

on couple So questions Apomorphine. just of a

the be? in And what’s to it one. Should pricing? the I about too what lines a and So way what best number think way give about or it – – might DVS what’s think cost the one, the best That’s to talk this, address but would a pump on more it early thought about the Duopa, to about you think to to way how Can best that? go. of we number the infusion I’d be of

infusion about of extent the diligence Number the you extent And but your the in the think of pump is was two in telling self-injection? you we what extent talked is, to can And which Thanks. could of terms cannibalize about this past, talk overlap? think, the you what overlapping? I the

Jack Khattar

final Yes, if do therapies expect, positioning and get going product out sure. depend the we go regarding FDA lot the label, be within kind the the Yes, pump, far launching is label will to as by would on and as the you a approved and we David, of to paradigm mean, there. we where what different as to the as positioning of after I able will

I deep earlier the on mentioned regarding and in – tube. stimulation the gastric response brain question the the gastric call surgical to the

the you So account as realm as clearly so Phase as pricing and to forth. data into that III mean, within take well far I have specifically, all the of

a So me point. bit for hard little this it’s at

first the of be we work the don’t to done mean, me all, I little is we will or comments. And actually launch when irresponsible I specific want anybody we so will about one the what it’s other. will bit mislead for pricing to a price make way any yet, haven’t talk it only the know people and – products.

that launch to So bit when later have little I’ll product. it really can on question we to we one, when answer a the to push that

significant on on far are? on pen impact also can the given we the more Or to indication mild which more cannibalization, pen. far a they what to these moderate be are minor will clearly, to the which get space? label the and the cannibalization what have stages the in spectrum as the different moderate? was it determining Or whether question, patients the we in far cannibalization moderate on Are they to promote really and how are on will and says the as as label first As the will for, the severe? related or clearly indication Because positioning, product to that you the they the factor at all a the

mild, of moderate then side, maybe to So usage clearly, in mild to the more of that would moderate upper theoretically, the than on would severe shift expect, time pen. to pump the we expect the over expand the more APOKYN the we be could and the could or a in side. the that moderate bit in because the coming although, Pen are little the that products other more marketplace dynamics is the And side space, on

forth modeled Is us. overlap. we’ve hard obviously. be It’s There’s transaction, this really move obviously When with XX% the to on and obviously. the franchise. up with cannibalization? And a current a will So naturally. eventually came huge to going going forward some be at build solid XXX%, a not ways and for that, us pump it looked there cannibalize We’ve case It’s modeled so at obviously different will different to for a be looking it with it incremental it some we XX%? scenarios this. Is very overlap

significant So looking definitely to franchise you’re net-net, overall. the at growth

David Amsellem

That’s Okay. helpful.

follow-up. Let that for And data me of continuous pretty sneak about a a nausea. your nausea in the pump? profile talk on causes quick on you infusion what Apomorphine rates Can high confer like and better front? emesis the looks does

Jack Khattar

Yes. I well long mean, effects are – Apomorphine a pretty been for time. long, side have has established known been

are the As over you I side using pen, time, used more this Apomorphine, less becomes bit and time. a a patient, if we little is be will the patients time and the the impacted it far you’re mean, by you effects. new first But less effect clearly, over as – get do to

to it has a in quick people patients. that’s it why UPDRS product and is these really benefits. use time a loyalty. good actually, they I period very of see actually really active amazing for the in such becoming mean, through and And The wants the reduction it

and and build same. similar is used effects patients of that very for loyal think, the up over to efficacy side when of very get time, to side up expect become type and drug with initially So tolerance it to the the And franchise. infusing trying with infusion you pretty effects, Apomorphine, time. you’re the you’re the pump, put to going have I Naturally, I some they similar so mean, a continuously the over

different a like So the flow, is of injection it drug we the to But is expect don’t because not bolus that obviously is. pen it itself. remarkably continuous very overall be quick very,

So speak tolerated a you little data and on. bit used I comparison really and to solid more, it don’t so head-to-head to from have would [ph] expect get to although, people potentially a

David Amsellem

Thank you.

Operator

a come no now this just showing I’m turn We question from follow-up questions back further time. to at over into the I apologize. queue – as had I [indiscernible] do conference now Securities. like would a

Unidentified Analyst

Thanks for my taking questions.

deal. Just really the WorldMeds on back S

And for million MYOBLOC last just year. growing dargo? strategy year? the the the last was your mentioned of sounds $XXX You were wondering, what APOKYN what’s did I also, [ph]

Jack Khattar

Yes. approximately million. The APOKYN. about total approximately $XXX in $XXX is or said, in $XXX it was million XXXX, We business

naturally, So remaining is the and between MYOBLOC XADAGO.

as As fairly a new. little the it’s same timing went – a or entry of It was molecule, Unfortunately, time. generic a that launched about business, before the for XXXX, bit product. actually is XADAGO bit was not far to the the so it’s in because elected perfect new that it’s little time fairly as

an of which for new inhibitor. XADAGO such with So a monoamine as that created a product, mechanism issue action, a is oxidase

oxidase Now, XADAGO in glutamatergic safinamide, monoamine to is It actually, addition which inhibition. is the activity a have dual mechanism. the action does the drug, on activity

differentiating it other inhibitor. you did the about product it potentially that label. from up end However, can not monoamine oxidase the on And promotional perspective what and that’s why limited from say a

from There oxidase inhibitors So ways would where generics. monoamine I looking been for situation push like other basically certainly we given put – – that. extra to products. the behind perspective, has the product, push limitations mentioned, We payer a other potentially certainly be the are with rejuvenate some

of from are So you would anyway that – you kind pushback expect payers. the

see we can will how we the product it and working the be actually So potentially improve traction to significantly. behind grow

Unidentified Analyst

Can I it dyskinesias? doing include whether follow-up? – could does to reduce just additional study maybe that That make a explore an

Jack Khattar

everything, a all. If would that this fully include not opportunity will product is clinically at have we our there another own. we partner. Obviously, is to We not work look It with new to generate data, promotional. just

So about speak far at know anything don’t this plans. partners, to We we have our with have specifically at point work really already as and as Zambon, not to to may when they this able point.

Unidentified Analyst

much. very Thanks Great.

Operator

I’ll showing turn the I’m further Mr. Khattar. no questions this conference now back to time. And at

Jack Khattar

expected of second flow. acquisition Thank which CNS we will the portfolio products, US the quarter neurology is a portfolio year, in have revenues, this our the the earnings five of you. cash After of of and of our completion marketed WorldMeds, diversifying

for plans team by In of about level the quality excited launch are the we SPN-XXX. our addition, preparation and our commercial very of

product, As when expect we FDA. approved get by to the to closer launch the we year-end the if

continue CNS. that, look this position Finally, of launch the Infusion what exciting our another to future in Thank strengthen are and opportunities for will to start to waiting the acquisition all our second you to addition finally, leadership strategic forward us to the of closing in and we we we XXXX throughout the be you Pump. Apomorphine second-half morning, updating for joining the of for further year. in planning look for could And growth

Operator

and And ladies for concludes have and day. gentlemen, wonderful a this Thank participation, today’s you conference.

disconnect. all may You

Supernus Pharmaceuticals (SUPN) 6 May 202020 Q1 Earnings call transcript